# US 2019/0167694 A1 · New therapeutics uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167694 A1
- Document ID: US20190167694A1
- Status: Published application
- Kind: A1
- Application number: 16/142,133
- Filed: 2017-04-05
- Published: 2019-06-06
- Earliest claimed: 2016-04-08
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Yong Jia; GERALD LELAIS; THOMAS HERBERT MARSILJE, III; ANDREW TODD MILLER; SHAILAJA KASIBHATLA
- Web page: https://patentgrep.com/patent/US20190167694A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

New uses of an EGFR inhibitor are disclosed. Methods of treatment using the EGFR inhibitor are also disclosed.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3

A method for the treatment of a T cell-mediated autoimmune disease comprising administering a therapeutically effective amount of the compound (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1 H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (nazartinib), or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

### Claim 4

(canceled)

### Claim 5 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is selected from ulcerative colitis, rheumatoid arthritis, Myasthenia gravis, Hashimoto's thyroiditis, polymyositis, Type I diabetes, celiac disease, multiple sclerosis, N-infectious uveitis, Sjögren's syndrome, primary biliary cirrhosis, autoimmune hepatitis and ankylosing spondylitis.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is selected from rheumatoid arthritis, Myasthenia gravis, Hashimoto's thyroiditis, polymyositis, Type I diabetes, celiac disease, multiple sclerosis, N-infectious uveitis, Sjögren's syndrome, primary biliary cirrhosis, autoimmune hepatitis and ankylosing spondylitis.

### Claim 7 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is selected from ulcerative colitis, Myasthenia gravis, Hashimoto's thyroiditis, polymyositis, celiac disease, N-infectious uveitis, Sjögren's syndrome, primary biliary cirrhosis, autoimmune hepatitis and ankylosing spondylitis.

### Claim 8 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is selected from ulcerative colitis, Myasthenia gravis, Hashimoto's thyroiditis, polymyositis, celiac disease, N-infectious uveitis, Sjögren's syndrome, primary biliary cirrhosis, and ankylosing spondylitis.

### Claim 9 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is ulcerative colitis.

### Claim 10 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is Myasthenia gravis.

### Claim 11 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is Hashimoto's thyroiditis.

### Claim 12 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is polymyositis.

### Claim 13 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is celiac disease.

### Claim 14 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is N-infectious uveitis.

### Claim 15 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is Sjögren's syndrome

### Claim 16 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is primary biliary cirrhosis.

### Claim 17 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is ankylosing spondylitis.

### Claim 18 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is autoimmune hepatitis.

### Claim 19 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is Type I diabetes.

### Claim 20 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is multiple sclerosis.

### Claim 21 (depends on 3)

The method according to claim 3, wherein the T cell mediated autoimmune disease is rheumatoid arthritis.